Latest News
Gina Della Porta, left, Director of the Office of Research Affairs, and David Stern, Professor of Pathology and Vice Chair for Basic and Translational Sciences, who oversees the office. In just one year, the Department of Pathology’s Office of Research Affairs has made an impact.
- February 21, 2022
Three Yale Pathology faculty members were recently honored for their contributions to cancer research and education during the Yale Cancer Center Annual Conclave on February 15, 2022.
- March 03, 2020
This Department of Defense award goes to the “best and brightest in their fields,” and recognizes “creative and innovative individuals.” Investigators are chosen for their ability “to go beyond conventional thinking” in their respective areas of expertise.
- February 14, 2018
The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer Hospital and Yale Cancer Center, hosted a major interdisciplinary conference addressing topics at the cutting edge of cancer policy. This event brought together leading figures in the worlds of cancer care, research, regulation, and policymaking to assess the current state of cancer policy and discuss ways in which law can influence its development.
- June 01, 2016Source: New Haven Register
Collaboration, directing federal money to small, innovative companies and lightening restrictions on basic research were among the points made during a “cancer moonshot” roundtable held Tuesday at the Yale School of Nursing.
- May 31, 2016Source: The Hartford Courant
Dr. Roy Herbst, chief of medical oncology at Yale's Smilow Cancer Hospital, is running one site of a lung cancer clinical trial that fits exactly into the goals of the Obama administrations' new cancer moonshot.
- May 12, 2016
Yale Cancer Center's Drs. David Stern, Roy Herbst, and Howard Hochster are on Capitol Hill today for American Association for Cancer Research (AACR)'s Hill Day. During Hill Day the team is visiting with Connecticut's representatives and staff to talk about the importance of funding for cancer research and patient programs and to provide an update on the impact Yale Cancer Center and Smilow Cancer Hospital are having in the fight against cancer.
- May 03, 2016
Yale Cancer Center is distinguished by its commitment to translational medicine—that is, to turn promising laboratory breakthroughs into new cancer therapies. To that end, Yale’s scientists and clinicians work closely together on Disease Aligned Research Teams, or DARTs, each devoted to specific cancer types.
- June 05, 2015Source: Association of American Cancer Institutes
More than 70 cancer center directors, physicians, researchers, and advocates representing 25 states visited Capitol Hill on May 7 to urge legislators to provide stable, predictable support for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) in Fiscal Year 2016. The event allowed advocates to participate in nearly 150 meetings with members of Congress and their staff, including leadership and key committee staff.
- May 01, 2014
The rallying cry at Yale Cancer Center is “translational medicine”—that is, moving research swiftly from the lab to the clinic so that patients can benefit from breakthrough therapies.